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Abstract
Purpose Chemotherapy for advanced pancreatic cancer has limited efficacy due to the difficultly of treating established 
tumours and the evolution of tumour resistance. Chemotherapies for pancreatic cancer are typically studied for their cytotoxic 
properties rather than for their ability to increase the immunogenicity of pancreatic tumour cells. In this study Gemcitabine in 
combination with immune modulatory chemotherapies Oxaliplatin, zoledronic acid and pomalidomide was studied to deter-
mine how combination therapy alters the immunogenicity of pancreatic tumour cell lines and subsequent T-cell responses.
Methods Pancreatic tumour cell lines were stimulated with the chemotherapeutic agents and markers of immune recognition 
were assessed. The effect of chemotherapeutic agents on DC function was measured using uptake of CFSE-stained PANC-1 
cells, changes in markers of maturation and their ability to activate CD8+ T-cells. The effect of chemotherapeutic agents on 
T-cell priming prior to activation using anti-CD3 and anti-CD28 antibodies was determined by measuring IFN-γ expression 
and Annexin V staining using flow cytometry.
Results These agents demonstrate both additive and inhibitory properties on a range of markers of immunogenicity. Gemcit-
abine was notable for its ability to induce the upregulation of human leukocyte antigen and checkpoints on pancreatic tumour 
cell lines whilst inhibiting T-cell activation. Pomalidomide demonstrated immune modulatory properties on dendritic cells 
and T-cells, even in the presence of gemcitabine.
Discussion These data highlight the complex interactions of different agents in the modulation of tumour immunogenicity 
and immune cell activation and emphasise the complexity in rationally designing chemo immunogenic combinations for 
use with immunotherapy.
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Introduction
Despite recent advances in cancer treatment, systemic 
chemotherapy still remains the only option for unresectable 
or metastatic pancreatic cancer. Folinic acid, fluorouracil, 
irinotecan and Oxaliplatin [1] (FOLFORINOX) or Gem-
citabine (GEM) in combination with Paclitaxel [2] are the 
main chemotherapeutic options available however due to 
the toxicities associated with these drugs GEM alone has 
typically been prescribed in approximately 46% of patients 
[3]. Even with greater first line options approximately 32% 
of patients receive gemcitabine monotherapy as first or 
second line treatment [4]. Pancreatic cancer quickly devel-
ops resistance to these chemotherapeutic regimens, limiting 
their efficacy. The median survival after pancreatic cancer 
diagnosis is approximately 4.6 months [5] which emphasises 
the urgent need for more effective treatment options. Thus, 
new chemotherapeutic regimens are required with improved 
efficacy [6].
The clinical potential of immunotherapy is being realised 
through the use of checkpoint inhibitors (CPI) and engi-
neered T-cells [7]. However, with very few exceptions, these 
immunotherapeutic approaches have not been particularly 
successful when applied to pancreatic cancer [8], likely 
due to the late presentation of the disease by which point 
the tumour is often locally advanced with a well-developed 
immune suppressive microenvironment [9]. CPI in combi-
nation with single agent GEM or GEM plus Paclitaxcel has 
repeatedly failed to show significant efficacy in pancreatic 
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cancer patients [10–16] indicating that new chemotherapeu-
tic approaches are needed for subsequent combination with 
immunotherapy.
Chemotherapeutic combinations for pancreatic cancer 
have typically been studied for their cytotoxic properties 
rather than their ability to increase the immunogenicity of 
pancreatic tumour cells. Our group has previously demon-
strated immune modulatory properties of GEM [17] indicat-
ing that it may be a suitable chemotherapeutic with which to 
develop novel combinations of immune modulating chem-
otherapeutic agents in the setting of pancreatic cancer. In 
this study chemotherapeutic agents Pomalidomide (POM), 
Oxaliplatin (OXP) and Zoledronic acid (ZA) were selected 
to be paired with GEM on the basis of their varied immune 
modulatory properties [18–21]. In this study the effect of 
these GEM-based combinations was assessed in vitro on 
markers of immunogenicity in pancreatic tumour cell lines, 
dendritic cells and T-cells.
Methods
Reagents
Gemcitabine, Oxaliplatin, Pomalidomide and ZAedronic 
acid, Staphylococcus enterotoxin B (SEB) and WST-1 rea-
gent were purchased from Sigma (Dorset, UK). Flow cytom-
etry antibodies were purchased from Biolegend (London, 
UK) and R and D systems (Abingdon, UK). Cytomegalovi-
rus, Epstein Barr Virus and Influenza virus (CEF) peptides 
were purchased from Sigma (Dorset, UK). CFSE reagent 
was purchased from Fisher Scientific—UK Ltd (Loughbor-
ough, UK).
Cell culture
Pancreatic tumour cell lines PANC-1, Miapaca-2 and 
BxCP-3 were cultured in Dulbecco’s modified eagles 
medium (DMEM) with 10% FBS and 5% Penicillin/Strep-
tomycin at 37 °C, 5%  CO2. Leukocyte cones obtained from 
the NHS national blood service (London, UK). PBMC were 
isolated using Histopac purchased from Sigma (Dorset, UK) 
as described previously [22].
Cytotoxicity assay
WST-1 viability assays were performed as detailed in the 
manufactures protocol. Briefly, pancreatic tumour cell lines 
were seeded into flat bottom 96 well plates at a concentration 
of 5 × 103 cells in 100 μl of DMEM. After overnight adher-
ence the tumour cells were treated with the indicated con-
centration of chemotherapeutic agents and incubated for a 
further 72 h. Supernatant was removed prior to incubation of 
the cells in WST-1 reagent (Sigma, Dorset, UK) for 20 min. 
Colour change was assessed using a spectrometer at 490 nm.
Generation of MDDC and T‑cells
MDDC were generated by isolating CD14+ cells using 
MACS CD14 isolation beads (Miltenyi, Bergisch Gladbach, 
Germany). The isolated cells were incubated with IL-4 and 
GMCSF for 6 days as previously described [22]. T-cells 
were isolated by positive selection using MACS CD3 isola-
tion beads according to the manufacturer’s instructions.
Flow cytometry
Pancreatic tumour cell lines, MDDC and T-cells were 
assessed for expression of different markers using the fol-
lowing antibodies: Anti-PDL-1 APC, anti-Galectin 9 PE, 
anti-CD39 FITC, anti-CD47 Percp-Cy5.5, anti-HLA-class 
I Alexa Flour 700, anti-MIC A/B PE, anti-ULBP1 FITC, 
anti-ULBP 2,5 6 Percp, anti-ULBP 3 APC,anti-CD86 PE, 
anti-CCR7 PE-CY7, anti-CD40 APC, anti-HLA-class II 
PE-CY5 anti-IFN-γ PE-CY7, anti-CD3 Alexa Flour 488, 
anti-CD4 APC-CY7, anti-CD8-PE and anti-CD69 APC 
(Biolegend, CA).
Tumour cell uptake assay
PANC-1 tumour cells were incubated with 1 µM of CFSE 
reagent overnight. Cells were subsequently washed in PBS 
and incubated with indicated concentration of chemothera-
peutic agents for 24 h. The cells were washed twice and 
incubated with 1 × 105 MDDC for 4 h. The non-adherent 
MDDC were stained with an PE-CY5 anti-human HLA-
class II antibody and assessed for uptake of CFSE labelled 
PANC-1 cells by flow cytometry (Biolegend, CA).
MDDC maturation
MDDC were incubated with supernatant from treated or 
untreated pancreatic tumour cell lines for 24 h prior to stain-
ing with antibodies specific for CD83, CD86, CCR7, PDL-1, 
HLA-class I, CD40 and HLA-class II (Biolegend, CA)..
T‑cell activation
DC were matured as described above and loaded with CEF 
peptide or SEB antigen prior to co-culture with autologous 
CD14 negative PBMC. Brefeldin A was added after 18 h 
and the cells were incubated for a further 6 h prior to stain-
ing with antibodies for anti-human-CD3 FITC, anti-human, 
anti-human CD8-PE, anti-human IFN-γ-PE-CY7. Puri-
fied T-cells were also directly treated with combinations of 
chemotherapeutic agents for 24 h and stained for anti-human 
Clinical and Translational Oncology 
1 3
CD69–APC. To measure the onset of activation induced cell 
death (AICD) anti-PD-1 (1–10 μg/ml), anti-CD3 (5 μg/ml) 
and anti-CD28 (2.5 μg/ml) antibodies were used to stimu-
late T-cells prior to staining with anti-IFN-γ PE-CY7 and 
Annexin V APC (Biolegend, CA).
Results
Markers of immunogenicity in pancreatic cell lines
Cytotoxicity by the selected chemotherapeutic agents against 
three pancreatic tumour cell lines PANC-1, Miapaca-2 and 
Bxcp-3, was assessed (Fig. 1; Table 1). Consistent with 
previous studies GEM was cytotoxic towards these tumour 
cell lines which in turn demonstrated different susceptibil-
ity to GEM-based killing (Fig. 1a; Table 1). Combinations 
of GEM with either ZA or OXP had an additive effect on 
tumour cell cytotoxicity, lowering GEM’s EC50 (Table 1). 
In contrast POM only demonstrated a discernible cytotoxic 
effect either alone or in combination with GEM against Mia-
paca-1 cells (Table 1) consistent with our previous work 
combining GEM with lenalidomide, an immune modulatory 
drug similar to POM [23].
The ability of GEM to increase HLA-class I expres-
sion on pancreatic tumour cell lines was assessed. GEM 
increased HLA expression after 48 h stimulation of each 
of the cell lines studied (Fig. 1b, c). Interestingly increases 
in HLA appeared to be independent of the ability of GEM 
to kill tumour cells (Fig.  1b) occurring at sub-optimal 
Fig. 1  Effect of GEM on cytotoxicity and markers of tumour recogni-
tion. GEM (0.01–10 μM) was incubated with each pancreatic tumour 
cell line for 72 h prior to the addition of WST-1 reagent to measure 
cell viability (a). Expression of HLA (48 h) and cytotoxicity (72 h) of 
PANC-1 cells by different concentrations of GEM (b). Fold increase 
in the expression of HLA-class I, PDL-1 and CD47 by GEM in each 
cell line after 24 h incubation (c). N = a minimum of 3 experiments
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concentrations (10–100 nM) to induce cytotoxicity and at 
a time point before which cytotoxicity is observed. Incuba-
tion of GEM with each cell line increased the expression 
of HLA-class I, PDL-1 and CD47 on each tumour cell line 
(Fig. 1c). Concentrations of GEM (10 nM) unable to induce 
cytotoxicity were able to increase the expression of ULBP1, 
2, 5 and 6 in addition to MIC A/B (Fig. 2a). In contrast GEM 
stimulation resulted in a decrease in ULBP3. The ability of 
GEM to alter the expression of immune checkpoints was 
also assessed, of five checkpoints measured GEM signifi-
cantly increased the expression of PDL-1 and CD47 in each 
cell line studied but had no effect on the expression of CD39, 
Galectin 9 or HVEM (Figs. 1c, 2b). Neither OXP, ZA or 
POM could increase the expression of HLA-class I, ULBP’s, 
MIC A/B but didn’t significantly alter the ability of GEM to 
upregulate these receptors (Fig. 2). These data indicate that, 
of the agents studied, the ability to increase the expression 
of markers of tumour recognition was restricted to GEM.
Next, the ability of each chemotherapeutic agent to induce 
markers of ICD from pancreatic tumour cell lines was deter-
mined. GEM demonstrated an ability to induce the cell sur-
face expression of Calreticulin on PANC-1 tumour cell lines 
(Fig. 3a). Similar effects were observed with Miapaca-2 and 
Bxcp-3 cells (data not shown). OXP, an established inducer 
of ICD was also capable of promoting CRT translocation 
whereas neither ZA or POM induced observable CRT trans-
location. Secretion of ATP and HMGB1 are also established 
markers of ICD [24]. GEM, ZA and POM were unable to 
induce the expression ATP or HMGB1, in contrast to OXP 
(Fig. 3b, c). Combinations of chemotherapeutic agents had 
no additive effect on markers of ICD (data not shown).
Effect of chemotherapeutic agents on monocyte 
derived dendritic cells
PANC-1 cells were used to study the effect of GEM on func-
tional responses from immune effector cells (Fig. 3e). First, 
CFSE-stained PANC-1 cells were stimulated with either sin-
gle agent or GEM-based combinations for 24 and 48 h prior 
to co-culture with monocyte derived dendritic cells (MDDC) 
for 4 h (Fig. 3d, e). Stimulation of PANC-1 cells tended to 
increase their uptake into MDDC with statistically signifi-
cant increases observed for GEM (Fig. 3d) and OXP but not 
ZA (Fig. 3f). Combinations of agents did not increase uptake 
of PANC-1 cells into MDDC (data not shown).
We sought to determine whether treatment of pancreatic 
tumour cells with chemotherapy alters the maturation of 
MDDC exposed to their supernatants and whether direct 
incubation of MDDC with chemotherapeutic agents effects 
their maturation. Incubation of MDDC with supernatant 
from PANC-1 cells significantly reduced the expression 
of HLA-class I, HLA-class II, PDL-1 and CD40 compared 
to untreated MDDC (Fig. 4a, c, d, f). CCR7 and CD86 
expression was not significantly altered. The supernatant of 
PANC-1 cells treated with single agents had no effect on any 
marker with the exception of supernatant from POM treated 
PANC-1 cells which significantly increased the expression 
of CD40 compared to that of supernatant from untreated 
PANC-1 cells.
Treatment of PANC-1 cells with combinations of chemo-
therapeutic agents significantly increased the expression of 
MDDC markers of maturation. HLA-class I, class II, CD86 
and CCR7, but not CD40, expression could be significantly 
increased by incubation of MDDC with supernatants from 
PANC-1 cells treated with GEM-based combinations con-
taining ZA, POM and/or OXP (Fig. 4a, b, d–f) compared 
to supernatant from untreated PANC-1 cells. Next, MDDC 
were directly stimulated with chemotherapeutic agents and 
markers of maturation were assessed. Each agent, alone or 
in combination, significantly increased the expression of 
HLA-class I compared to the untreated control. In addition, 
combinations of GEM including ZA or POM significantly 
increased the expression of CD86 and CD40 respectively 
(data not shown). However, CCR7, HLA-class II, and PDL-1 
were unchanged.
Stimulation of MDDC with 100 ng/ml of the TLR4 
agonist LPS significantly increased the expression of 
each marker with the exception of CCR7 when compared 
to untreated or PANC-1 supernatant incubated MDDC. 
To assess the effect of TLR ligation in combination with 
chemotherapeutic agents Poly IC, a TLR3 agonist, was 
Table 1  EC50 of different 
chemotherapeutic agents on 
PANC-1, Miapaca-2 and 
BxCP-3 cell lines
Agent EC50 µM (95% CI) of agents against pancreatic tumour cell lines
PANC-1 Miapaca-2 Bxcp-3
Gemcitabine (GEM) 24.97 (9–38.4) 2.5 (1–7.1) 1.90 (0.4–11.8)
Oxaliplatin (OXP) 4.52 (3.2–6.5) 5.01 (1.5–22.3) 4.52 (3.2–6.5)
Zoledronic acid (ZA) 1.04 (0.5–21.4) 0.14 (0.06 to 0.2) 1.34 (0.6–2.76)
Pomalidomide (POM) NR 4.01 (1–22.6) NR
Gem + OXP (1 µM) 0.81 (0.05–9.9) 1.43 (0.7–3.9) 0.73 (0.1–6.8)
Gem + ZA (100 nM) 1.96 (0.88–4.8) 7.48 (1.8–52.2) 0.81 (0.05–9.9)
GEM + POM (10 µM) 20.65 (5.17–31.8) 2.84 (0.8–13) 1.31 (0.1–21)
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combined with single agent GEM, which had demon-
strated no effect on DC maturation or POM which had 
demonstrated limited effects on DC maturation (Fig. 4e). 
Poly IC plus either GEM or POM resulted in increases in 
markers of MDDC maturation compared to the no stimula-
tion control (Fig. 4g).
Effect of chemotherapeutic agents on T‑cell 
responses
Next, the ability of treated MDDC to stimulate antigen spe-
cific CD8+ T-cell responses was assessed (Fig. 5). MDDC 
incubated with supernatant from treated PANC-1 tumour 
cells or directly stimulated with chemotherapeutic agents for 
Fig. 2  GEM-based combination treatment and markers of tumour 
recognition. PANC-1 cells were treated for 48 h with different con-
centrations of GEM and changes in the expression of markers of 
tumour recognition HLA-class I, ULBP1, 3, 2/5/6 and MIC A/B (a) 
or immune checkpoints CD39, HVEM, PDL-1 (0.1  µM p = 0.007, 
1  µM p = 0.006, 1  µM p = 0.014) Galectin 9 and CD47 (0.1  µM 
p = 0.007, 1 µM p = 0.006, 1 µM p = 0.05) were measured (b). N = 3. 
GEM (100  nM), OXP (100  nM), ZA (10  nM) and POM (100  nM) 
were used alone or in combination to stimulate PANC-1 cells for 48 h 
and markers of tumour recognition were measured by flow cytometry. 
N = 3. Paired t tests were performed to assess statistical significance
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24 h were co-cultured with a peptide pool containing immu-
nodominant epitopes from cytomegalovirus, Epstein Barr 
virus and influenza virus (CEF) and co-cultured with PBMC 
for a further 24 h. Intracellular cytokine staining was used to 
assess the antigen specific expression of IFN-γ from CD8+ 
T-cells (Fig. 5). Consistent with the ability of combination 
agents to induce MDDC maturation, combinations includ-
ing GEM and POM with either ZA or OXP significantly 
increased the expression of IFN-γ from CD8+ T-cells. Sin-
gle agent POM was able to stimulate increased CEF depend-
ent expression of IFN-γ from CD8+ T-cells whereas single 
agent GEM reduced IFN-γ expression (Fig. 5b, c). To assess 
the direct effect of POM on T-cell activation, isolated T-cells 
were incubated with POM (1–100 nM) and CD69 expres-
sion was assessed (Fig. 5g). POM significantly increased the 
expression of CD69 on CD8+ T-cells (Fig. 6f). Combining 
POM with GEM showed that whilst GEM had no significant 
effect on CD69 expression it could partially block the effect 
of POM. Taken together these data suggest an inhibitory 
effect of GEM on T-cell activation.
CD8+, CD101+ T-cells expressing CD38 and PD-1 have 
been associated with poor prognosis in pancreatic cancer 
Fig. 3  Induction of markers of immunogenic cell death from chemo-
therapeutic agents. Calreticulin (a) (0.1  µM GEM p = 0.04, 1  µM 
GEM p = 0.04; 1 µM OXP p = 0.016), ATP (b) (10 µM OXP p = 0.05) 
and HMGB1 (c) (0.1  µM GEM p = 0.0073, 1  µM GEM p = 0.013; 
1  µM OXP p = 0.018) were measured in PANC-1 cells stimulated 
with different chemotherapeutic agents for 24–48  h. N = at least 3 
experiments. A paired t test was used to determine statistical signifi-
cance over unstimulated control. CFSE-stained PANC-1 cells treated 
with chemotherapeutic agents for 24 or 48 h were incubated for 4 h 
with MDDC and uptake was measured by flow cytometry. Incuba-
tion of CFSE + PANC-1 cells with chemotherapeutic agents promotes 
their internalisation by HLA-DR hi MDDC (d). Effect of uptake 
of PANC-1 cells at 24 and 48  h stimulation GEM (0.1  µM GEM 
p = 0.008, 1  µM GEM p = 0.027; 10  µM GEM p = 0.029) (e). GEM 
and OXP but not ZA promote PANC-1 uptake by DC (f)
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Fig. 4  GEM-based combinations enhance DC maturation: Immature 
MDDC were cultured with supernatant from pancreatic tumour cells 
treated with GEM-based combinations or left untreated. No superna-
tant (No stimulation) and LPS were utilised as controls. Flow cytom-
etry was used to assess markers of maturation after 24 h HLA-class 
I (a), CD86 (b), CD40 (c), PDL-1 (d), CCR7 (e) and HLA-class II 
(f). N = experiments from 6 different donor PBMC. GEM (10 nM) or 
POM (10 nM) were paired with Poly IC (1 μg/ml) and incubated with 
MDDC for 24 h and markers of maturation were assessed (g). Paired t 
tests were used to assess statistical significance
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Fig. 5  Treatment with combinations of chemotherapeutic agents sig-
nificantly increases antigen specific IFN-γ expression from CD8+ 
T-cells. IFN-γ expression from CD8+ T-cells stimulated with treated 
MDDC expressing CEF epitopes (a). CD8+ T-cells were stimu-
lated with MDDC incubated with supernatant from PANC-1 cells 
treated with GEM, ZA or POM (b) or with MDDC directly stimu-
lated with GEM, ZA, POM (c) and loaded with CEF peptide. CD8+ 
T-cells were stimulated with MDDC incubated with supernatant from 
PANC-1 cells treated with GEM, OXP or POM (d) or with MDDC 
directly stimulated with GEM, OXP, POM (e) and loaded with CEF 
peptide. N = at least 6 experiments. Isolated T-cells were stimulated 
with POM for 24 h and CD69 expression on CD8+ T-cells was meas-
ured by flow cytometry (f). CD69 expression from CD8+ T-cells 
stimulated for 24 h with GEM ± POM (g). N = 4
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[25]. CD101 is a marker of T-cell exhaustion [26] and CD38 
and PD-1 co-expressing T-cells are thought to be dysfunc-
tional [27]. We sought to determine whether GEM pre-stim-
ulation followed by T-cell activation could cause increases 
in CD38 and PD-1 expression on T-cells. Activation of 
T-cells with anti-CD3 plus anti-CD28 antibodies increased 
the expression of CD38 and PD-1; however, preincubation 
with gemcitabine resulted in no additional expression 
either CD4+ or CD8+ T-cell subsets. POM significantly 
increased the expression of IFN-γ from effector and central 
memory CD8+ T-cell populations, consistent with its ability 
to increase IFN-γ expression from CEF stimulated T-cells 
(Fig. 6) but did not significantly increase the expression of 
CD38 and PD-1 (data not shown). The frequency of CD101 
Fig. 6  Pomalidomide modulates activation of CD8 + T-cells pre-incu-
bated with anti-PD-1 antibody. T-cells were incubated with anti-PD-1 
(10 μg/ml) ± GEM (1–100 nM) or POM (1–100 nM) or combinations 
of GEM (10 nM) and POM (10 nM) for 48 h prior to activation with 
anti-CD3 and anti-CD28 antibodies for a further 48 h (a). Effect of 
Anti-PD-1 pre-stimulation ± POM or GEM on IFN-γ expression (b), 
or Annexin V expression (c) from CD8+ T-cells. N = 4
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on T-cell subsets was not changed by preincubation with 
POM or GEM and the expression of CD38 and PD-1 on 
CD101+ cells was also unchanged.
Finally, checkpoint blockade with anti-PD-1 antibodies 
has been implicated in the onset of dysfunction and apopto-
sis of T-cells associated with poor prognosis in PDAC [27]. 
Consistent with these findings we found that preincuba-
tion of anti-PD-1 antibody (10 μg/ml) followed by T-cell 
activation resulted in increases in Annexin V staining and 
reductions in IFN-γ expression in CD8+ T-cells (Fig. 6). 
The ability of GEM or POM to co-stimulate T-cells in the 
presence of anti-PD-1 antibody was measured. Incubation 
of T-cells with GEM + anti-PD-1 antibody prior to T-cell 
activation resulted in reductions in both IFN-γ and Annexin 
V staining (Fig. 6b, e). In contrast incubation of T-cells 
with POM + anti-PD-1 antibody reduced the expression of 
Annexin V staining compared to anti-PD-1 incubation alone 
whilst increasing the expression of IFN-γ in CD8+ T-cells 
(Fig. 6c, f) but not CD4+ T-cells. Incubation of Pom with 
GEM + anti-PD-1 antibody was able to recapitulate IFN-γ 
expression in CD8+ T-cells but was unable to reduce the 
expression of Annexin V (Fig. 6d, g).
Discussion
Improving the immune modulatory properties of GEM-
based therapy will benefit pancreatic cancer patients by 
providing more effective chemo-immunotherapy based 
treatments capable of killing tumour cells through direct 
cytotoxic effects and by supporting anti-tumour immune 
responses activated with immunotherapies such as check-
point inhibition [28, 29].
This study demonstrates the complexity of combining dif-
ferent agents with varied effects on diverse markers of the 
immune response. Of the agents studied here GEM was 
unique in its ability to upregulate markers of tumour rec-
ognition from pancreatic tumour cell lines including HLA-
class I, MIC A/B and ULBP receptors (Figs. 1, 2). It would 
be interesting to ascertain whether GEM can enhance the 
targeting of pancreatic tumour cells by effector cells capable 
of recognising MIC A/B and ULBP such as NK and γδ-T-
cells. GEM was the only agent studied which upregulated 
checkpoint molecules including PDL-1 and CD47. This has 
relevance for its potential as an immunotherapeutic agent 
in combination with anti-PD-1 or anti-PDL-1 inhibitors 
whilst implicating these checkpoints in blocking putative 
immune potentiating properties of GEM in vivo. Notably 
GEM could induce increases in HLA expression at concen-
trations inducing minimal cytotoxicity (Fig. 1) indicating 
that the immunogenic and cytotoxic properties of GEM may 
be independent. These data have implications for the use and 
dose of GEM in different therapeutic settings.
In contrast GEM was unable to induce expression of all 
three markers of ICD. Oxaliplatin, capable of ICD, increased 
the expression of CRT, ATP and HMGB1 from pancreatic 
tumour cell lines, in line with previous studies [30]. GEM 
increased the expression of CRT on the surface of pancreatic 
tumour cells and enhanced the uptake of PANC-1 cells into 
DC but could not induce the expression of ATP or HMGB1 
from the cell lines studied (Fig. 3). Given the ability of GEM 
to increase the expression of the checkpoint CD47 which is 
involved in blocking the CRT dependent uptake of tumour 
cells it would be interesting to ascertain whether blocking 
CD47 expression on PANC-1 cells further enhanced their 
GEM mediated uptake into APC’s.
Combination treatment of PANC-1 cells induced factors 
that could significantly increase the expression of markers of 
DC maturation compared to no treatment controls or single 
agent GEM (Fig. 4). These increases were lower compared 
to LPS or Poly IC but were associated with a significantly 
increased ability of these DC to activate antigen specific 
IFN-γ expression from CD8+ T-cells (Fig. 5). The increases 
in both DC maturation and T-cell activation were likely due 
in part to the presence of the iMiD POM in the combina-
tion treatment, consistent with our previous findings [20]. 
GEM alone was unable to either induce DC maturation or 
activation of T-cell responses. GEM, but not OXP or ZA, 
was associated with inhibition of T-cell activation (Figs. 5, 
6) suggesting a potential role for GEM in T-cell dysfunction.
Dysfunctional T-cell subsets, defined by expression 
of PD-1 and CD38 are associated with poor prognosis in 
GEM treated pancreatic patients, particularly on CD101+ 
expressing T-cells which represent an exhausted phenotype 
that cannot be salvaged by anti-PD-1 therapy [26]. A recent 
study indicated that  CD38hi, PD-1hi T-cells are susceptible to 
apoptosis upon interaction with anti-PD-1 antibody prior to 
T-cell priming [27]. Incubation with GEM and/or POM did 
not significantly alter the expression of these markers upon 
stimulation of T-cell subsets from healthy donors. However, 
GEM inhibited IFN-γ expression from T-cells which could 
be partially restored with POM co stimulation (Fig. 6d). 
POM was also capable of reducing the onset of markers of 
apoptosis and increase the expression of IFN-γ from T-cells 
incubated with anti-PD-1 antibody prior to T-cell activa-
tion (Fig. 6b, e) consistent with the ability of POM to prime 
T-cell responses.
Its notable that GEM had the greatest effect on markers 
of tumour recognition, OXP on markers of ICD and POM 
on the priming of T-cell immune responses. Combinations 
of these agents rarely demonstrated additive or inhibi-
tory properties, with the exception of GEM dependent 
inhibition of T-cell responses. Although several chemo-
therapeutics have well defined immunogenic effects their 
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clinical efficacy has rarely been associated with the onset 
of immune responses, even for known inducers of ICD. 
A possible explanation for the limited observable immu-
notherapeutic effects of chemotherapeutic agents is that 
the promotion anti-tumour immune responses involves a 
multitude of checkpoints and effector cells whilst a single 
agent such as GEM mediates only a subset of these factors. 
The agents studied here demonstrated modest ability to 
induce markers of ICD (Fig. 3) or DC maturation (Fig. 4), 
suggesting that this component of chemo-immunotherapy 
needs to be addressed. Combinations involving chemother-
apy and broad immune stimulants including TLR agonists 
such as Poly IC [31, 32] or cytokines such as IFN-α [33] 
have shown promise and the combination of GEM or POM 
with Poly IC studied here demonstrated increased DC mat-
uration (Fig. 4g). The potential therapeutic benefit of com-
bination of chemotherapy with TLR agonists is illustrated 
by our recent study demonstrating improved responses in 
PDAC patients with the addition of heat killed supported 
Mycobacterium obuense to single agent GEM [34].
A greater understanding of the immunological effects of 
combination chemotherapy, in addition to factors such as 
dose and sequence, is likely needed to improve immunother-
apy in cancers such as pancreatic cancer. These data high-
light that chemotherapeutics such as GEM can benefit by 
the addition immune modulators capable of inducing strong 
DC maturation and T-cell activation. It will be interesting to 
study the effect of these combinations in vivo during which 
the activation of tumour recognition and ICD, DC matu-
ration and activation of T-cell responses may demonstrate 
cumulative anti-tumour effects which are not possible to 
study using the in vitro assays described here.
Checkpoint inhibition has demonstrated poor efficacy 
against pancreatic cancer. Priming with immune modulatory 
agents [34] followed by immunogenic chemotherapy such 
as with GEM plus POM may promote greater effectiveness 
of checkpoint inhibition. We have previously reported on a 
complete response (>2 years) in a case study of metastatic 
pancreatic cancer involving treatment with enalidomide, 
GEM and a heat killed preparation of Mycobacterium vac-
cae. In a more recent case study a complete response was 
observed involving GEM and Mycobacterium obuense by 
the CPI Pembrolizumab (unpublished observation). In con-
clusion, this study has demonstrated distinct in vitro immune 
modulatory effects of GEM and POM on pancreatic tumour 
cell lines and T-cells respectively. This indicates that these 
agents are suitable for combination with immunotherapy 
such as checkpoint inhibition, particularly alongside innate 
immune agonists capable of promoting immunogenic cell 
death or DC maturation.
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